Live tape
Top 8, mentions 7d15,447NVDA4,382 mentions▲ +0.04GOOGL2,567 mentions▲ +0.04AMD1,925 mentions▲ +0.08SPY1,738 mentions▲ +0.06QQQ1,668 mentions▲ +0.05SPCX1,134 mentions▲ +0.06TSLA1,027 mentions▲ +0.05AAPL1,006 mentions▲ +0.05

Equity · Healthcare

SYRE

NASDAQ

Spyre Therapeutics (SYRE)

100 USD +6.38% vs prior close
Spyre Therapeutics, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for SYRE to draw a line in its place.

Track this symbol on TradingView
Market cap
9.5B USD
Revenue, year to Dec 2025
0 USD
52-week range
15 USD – 102 USD
Avg volume
393.0K

as of Jul 17, 2026

Have Spyre Therapeutics (SYRE) insiders bought or sold shares recently?

In the 90 days to 10 Nov 2026, Spyre Therapeutics insiders reported 9 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 3 Nov 2025, show no open-market purchase.

Form 4, 90 days to 10 Nov 2026, newest reported trade 1 Oct 2026

Buys 0Sells 9Net sold $12.35MOther filings 6

Have Spyre Therapeutics (SYRE) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
01 Oct 2026Burrows Scott LChief Financial OfficerSell7,500689K USD
01 Oct 2026King-Jones HeidySee RemarksSell28,9332.6M USD
01 Oct 2026Turtle CameronChief Executive OfficerSell15,0001.4M USD
30 Sep 2026Burrows Scott LChief Financial OfficerSell17,5001.6M USD
02 Sep 2026Burrows Scott LChief Financial OfficerSell18,2321.6M USD
02 Sep 2026King-Jones HeidySee RemarksSell40036K USD
01 Sep 2026Burrows Scott LChief Financial OfficerSell7,500655K USD
01 Sep 2026King-Jones HeidySee RemarksSell27,9992.4M USD
01 Sep 2026Turtle CameronChief Executive OfficerSell15,0001.3M USD
Sold9 open-market sales138,064$12.35M
6 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Spyre Therapeutics (SYRE) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
01 Oct 2026Burrows Scott LChief Financial OfficerOption exercise7,500109K USD
01 Oct 2026King-Jones HeidySee RemarksOption exercise28,933420K USD
30 Sep 2026Burrows Scott LChief Financial OfficerOption exercise17,500254K USD
02 Sep 2026King-Jones HeidySee RemarksOption exercise4006K USD
01 Sep 2026Burrows Scott LChief Financial OfficerOption exercise7,500109K USD
01 Sep 2026King-Jones HeidySee RemarksOption exercise27,999406K USD

Which funds hold Spyre Therapeutics (SYRE)?

9 of the 45 institutional funds we track reported a Spyre Therapeutics position for the quarter ended 30 Jun 2026 — a combined 134.2M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Spyre Therapeutics (SYRE)?
FundPositionSharesValueShares q/q
Marshall WaceAdded991,69388.0M USD+612.1%
Millennium ManagementAdded196,71217.5M USD+34.1%
Balyasny Asset ManagementAdded147,04213.1M USD+165.1%
Citadel AdvisorsHeld (±25%)103,1009.2M USD−4.7%
D. E. Shaw & Co.New position26,4522.3M USD
AQR Capital ManagementHeld (±25%)22,9372.0M USD+9.9%
Two Sigma InvestmentsNew position12,7711.1M USD
Man GroupHeld (±25%)7,714685K USD−19.2%
Tudor Investment CorpTrimmed2,645235K USD−68.4%
Baker Bros. AdvisorsExited

What has been filed or recorded for Spyre Therapeutics (SYRE)?

The filings we hold for Spyre Therapeutics, newest first: 5 fails-to-deliver days, 6 quarterly earnings reports and 4 reported financial figures, the latest dated 14 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Spyre Therapeutics (SYRE)?
And
14 Oct 2026Fails to deliverShares failed to deliver363 shares29K USD notional · <0.001% of shares out
13 Oct 2026Fails to deliverShares failed to deliver466 shares40K USD notional · 0.001% of shares out
09 Oct 2026Fails to deliverShares failed to deliver3,534 shares282K USD notional · 0.004% of shares out
07 Oct 2026Fails to deliverShares failed to deliver63 shares5K USD notional · <0.001% of shares out
05 Oct 2026Fails to deliverShares failed to deliver269 shares25K USD notional · <0.001% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −2.04 USD
30 Sep 2026FinancialsTotal assets1.1B USDat period end
30 Sep 2026FinancialsTotal equity1.1B USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −1.09 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.74 USD
31 Dec 2025FinancialsRevenue0 USDfiscal year
31 Dec 2025FinancialsNet income−155.2M USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −1.24 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −1.09 USD
30 Sep 2024Quarterly earningsQ3 2024 reportedEPS 1.06 USD

Spyre Therapeutics (SYRE): frequently asked questions

From live data
9.5B

What is Spyre Therapeutics’ market cap?

Spyre Therapeutics is worth 9.5B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

0

What is Spyre Therapeutics’ revenue?

Spyre Therapeutics reported revenue of 0 USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

9 sales

Have Spyre Therapeutics insiders bought or sold shares recently?

In the 90 days to 10 Nov 2026, Spyre Therapeutics insiders reported 9 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 3 Nov 2025, show no open-market purchase. A further 6 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

9 of 45

Which funds own Spyre Therapeutics?

9 of the 45 funds we track reported a Spyre Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Marshall Wace, Millennium Management and Balyasny Asset Management. See Funds

−2.04

When did Spyre Therapeutics last report earnings?

Spyre Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −2.04 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings